NASDAQ:GLYC GlycoMimetics (GLYC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About GlycoMimetics Stock (NASDAQ:GLYC) 30 days 90 days 365 days Advanced Chart Get GlycoMimetics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.16▼$27.4752-Week Range N/AVolume1.05 million shsAverage Volume69,301 shsMarket Capitalization$10.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingModerate Buy Company OverviewGlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.Read More… GlycoMimetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreGLYC MarketRank™: GlycoMimetics scored higher than 22% of companies evaluated by MarketBeat, and ranked 827th out of 924 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for GlycoMimetics.Read more about GlycoMimetics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for GlycoMimetics are expected to remain at ($0.08) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of GlycoMimetics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlycoMimetics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about GlycoMimetics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.90% of the float of GlycoMimetics has been sold short.Short Interest Ratio / Days to CoverGlycoMimetics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GlycoMimetics has recently increased by 1.79%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGlycoMimetics does not currently pay a dividend.Dividend GrowthGlycoMimetics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.55 Percentage of Shares Shorted2.90% of the float of GlycoMimetics has been sold short.Short Interest Ratio / Days to CoverGlycoMimetics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GlycoMimetics has recently increased by 1.79%, indicating that investor sentiment is decreasing. News and Social Media1.1 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for GlycoMimetics this week, compared to 1 article on an average week.Search Interest1 people have searched for GLYC on MarketBeat in the last 30 days. MarketBeat Follows1 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GlycoMimetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.70% of the stock of GlycoMimetics is held by insiders.Percentage Held by Institutions75.19% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GlycoMimetics' insider trading history. Receive GLYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter. Email Address GLYC Stock News HeadlinesLifeSci Capital Initiates Coverage of GlycoMimetics (CBIO) with Outperform RecommendationJune 20 at 5:47 AM | msn.comGlycoMimetics (NASDAQ:GLYC) Stock Price Crosses Below 200 Day Moving Average - Should You Sell?June 20 at 4:11 AM | americanbankingnews.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.June 22, 2025 | Porter & Company (Ad)GlycoMimetics trading halted, news pendingJune 14, 2025 | msn.comGlycoMimetics (NASDAQ:GLYC) Shares Set to Reverse Split on Monday, June 16thJune 12, 2025 | americanbankingnews.comGlycoMimetics Stock Scheduled to Reverse Split on Monday, June 16th (NASDAQ:GLYC)June 12, 2025 | americanbankingnews.comCantor Fitzgerald Comments on GlycoMimetics FY2026 EarningsJune 12, 2025 | americanbankingnews.comGlycoMimetics announces 1-for-100 reverse stock splitJune 7, 2025 | investing.comSee More Headlines GLYC Stock Analysis - Frequently Asked Questions How were GlycoMimetics' earnings last quarter? GlycoMimetics, Inc. (NASDAQ:GLYC) announced its earnings results on Wednesday, May, 14th. The biotechnology company reported ($4.00) earnings per share for the quarter, beating analysts' consensus estimates of ($5.00) by $1.00. When did GlycoMimetics' stock split? GlycoMimetics's stock reverse split on Monday, June 16th 2025. The 1-100 reverse split was announced on Thursday, June 5th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are GlycoMimetics' major shareholders? GlycoMimetics' top institutional shareholders include Wellington Management Group LLP (2.12%) and Jefferies Financial Group Inc. (0.91%). Insiders that own company stock include Public Equities LP Invus, Edwin Rock, Bruce S Johnson and Brian M Hahn. View institutional ownership trends. How do I buy shares of GlycoMimetics? Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GlycoMimetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that GlycoMimetics investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Bristol Myers Squibb (BMY), Meta Platforms (META), Advanced Micro Devices (AMD) and Alibaba Group (BABA). Company Calendar Last Earnings5/14/2025Today6/22/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLYC CIK1253689 Webwww.glycomimetics.com Phone(240) 243-1201Fax301-738-2137Employees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$37.88 million Net MarginsN/A Pretax Margin-397,340.00% Return on Equity-230.74% Return on Assets-177.39% Debt Debt-to-Equity RatioN/A Current Ratio1.92 Quick Ratio1.92 Sales & Book Value Annual Sales$10 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / BookN/AMiscellaneous Outstanding Shares64,532,000Free Float58,901,000Market Cap$10.00 million OptionableOptionable Beta1.62 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:GLYC) was last updated on 6/22/2025 by MarketBeat.com Staff From Our PartnersWar Tensions Are Making Gold Rise to Record HighsIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.